Lack of Economic Benefit with Basiliximab Induction in Living Related Donor Adult Renal Transplant Recipients
Study Objective. To assess the effect of basiliximab (BAS) induction therapy on acute rejection rates and overall costs in adult living related donor (LRD) renal transplant recipients. Design. Retrospective chart review and cost‐effectiveness analysis of the first 12 months after transplantation. Se...
Gespeichert in:
| Veröffentlicht in: | Pharmacotherapy 2003-04, Vol.23 (4), p.443-450 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 450 |
|---|---|
| container_issue | 4 |
| container_start_page | 443 |
| container_title | Pharmacotherapy |
| container_volume | 23 |
| creator | Crompton, Jason A. Somerville, Troy Smith, Lonnie Corbett, Jacke Nelson, Edward Holman, John Shihab, Fuad S. |
| description | Study Objective. To assess the effect of basiliximab (BAS) induction therapy on acute rejection rates and overall costs in adult living related donor (LRD) renal transplant recipients.
Design. Retrospective chart review and cost‐effectiveness analysis of the first 12 months after transplantation.
Setting. University hospital and outpatient renal transplant clinic.
Patients. Sixty consecutive adult LRD renal transplant recipients.
Intervention. The treatment group received BAS 20 mg intravenously on postoperative days 0 and 4. The control group received no induction agents. Both groups received cyclosporine microemulsion, azathioprine, and corticosteroids for maintenance immunosuppression.
Measurements and Main Results. Six patients (three in each group) were excluded; three had received muromonab‐CD3 as an induction agent and three were lost to follow‐up. At 12‐months, the frequency of acute rejection episodes was 15% (4/27) in the control group and 22% (6/27) in the BAS group (NS). Renal function, as measured by average serum creatinine level, was similar at months 1, 2, 3, 6, and 12 for both groups. The frequency of infectious complications was similar in both groups. No adverse effects were associated with BAS. Mean initial hospitalization charges were $51,970.01 and $68,093.90 in the control and BAS groups, respectively (p |
| doi_str_mv | 10.1592/phco.23.4.443.32119 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73193452</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73193452</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4198-8cb74c6682b370e8a6aa5ba4931c0215c96002f47e9cba118456f95a607ed9cb3</originalsourceid><addsrcrecordid>eNqNkEtv1DAURi0EotPCL0BC3sAuwa_4sZwppVNpCnRUYGk5jkNNHSfESR__Hg8zoltWlq7OudffB8AbjEpcKfJhuLF9SWjJSsZoSQnG6hlYYCmqQmHMnoMFIkIUCCF5BI5T-oUQwZyRl-AIEy4RE2wBuo2xt7Bv4ZntY995C1cuutZP8N5PN3Blkg_-wXemhhexme3k-wh9hBt_5-NPuHXBTK6BH7M8wmUzhynPognwejQxDcHE3cD6wbs4pVfgRWtCcq8P7wn49uns-nRdbL6cX5wuN4VlWMlC2lowy7kkNRXIScONqWrDFMU2Z6is4jlLy4RTtjYYS1bxVlWGI-GaPKIn4P1-7zD2v2eXJt35ZF3I33H9nLSgWFFWkQzSPWjHPqXRtXoYc9jxUWOkdy3rXcuaUM10bln_bTlbbw_r57pzzZNzqDUD7w6ASdaENndhfXrimBBYKJk5tefufXCP_3Nbf10vt1iSnVvsXZ8m9_DPNeOt5oKKSv_4fK75ant1-f3ySq_pH99wp1U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73193452</pqid></control><display><type>article</type><title>Lack of Economic Benefit with Basiliximab Induction in Living Related Donor Adult Renal Transplant Recipients</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Crompton, Jason A. ; Somerville, Troy ; Smith, Lonnie ; Corbett, Jacke ; Nelson, Edward ; Holman, John ; Shihab, Fuad S.</creator><creatorcontrib>Crompton, Jason A. ; Somerville, Troy ; Smith, Lonnie ; Corbett, Jacke ; Nelson, Edward ; Holman, John ; Shihab, Fuad S.</creatorcontrib><description>Study Objective. To assess the effect of basiliximab (BAS) induction therapy on acute rejection rates and overall costs in adult living related donor (LRD) renal transplant recipients.
Design. Retrospective chart review and cost‐effectiveness analysis of the first 12 months after transplantation.
Setting. University hospital and outpatient renal transplant clinic.
Patients. Sixty consecutive adult LRD renal transplant recipients.
Intervention. The treatment group received BAS 20 mg intravenously on postoperative days 0 and 4. The control group received no induction agents. Both groups received cyclosporine microemulsion, azathioprine, and corticosteroids for maintenance immunosuppression.
Measurements and Main Results. Six patients (three in each group) were excluded; three had received muromonab‐CD3 as an induction agent and three were lost to follow‐up. At 12‐months, the frequency of acute rejection episodes was 15% (4/27) in the control group and 22% (6/27) in the BAS group (NS). Renal function, as measured by average serum creatinine level, was similar at months 1, 2, 3, 6, and 12 for both groups. The frequency of infectious complications was similar in both groups. No adverse effects were associated with BAS. Mean initial hospitalization charges were $51,970.01 and $68,093.90 in the control and BAS groups, respectively (p<0.05). The control group had more readmissions (18 vs 14 in the BAS group), but the average charge/readmission was lower ($10,148.50 vs $21,952.58 in the BAS group; NS). All costs were adjusted to 2000 dollars (US).
Conclusion. Basiliximab induction therapy did not provide clear clinical efficacy benefit or prove to be cost‐effective compared with no induction in LRD recipients.</description><identifier>ISSN: 0277-0008</identifier><identifier>EISSN: 1875-9114</identifier><identifier>DOI: 10.1592/phco.23.4.443.32119</identifier><identifier>PMID: 12680474</identifier><identifier>CODEN: PHPYDQ</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; Antibodies, Monoclonal - economics ; Antibodies, Monoclonal - therapeutic use ; Biological and medical sciences ; Chi-Square Distribution ; Confidence Intervals ; Cost-Benefit Analysis - methods ; Cost-Benefit Analysis - statistics & numerical data ; Female ; Graft Rejection - drug therapy ; Graft Rejection - economics ; Humans ; Kidney Transplantation - economics ; Kidney Transplantation - statistics & numerical data ; Living Donors - statistics & numerical data ; Male ; Medical sciences ; Middle Aged ; Recombinant Fusion Proteins ; Retrospective Studies ; Statistics, Nonparametric</subject><ispartof>Pharmacotherapy, 2003-04, Vol.23 (4), p.443-450</ispartof><rights>2003 Pharmacotherapy Publications Inc.</rights><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4198-8cb74c6682b370e8a6aa5ba4931c0215c96002f47e9cba118456f95a607ed9cb3</citedby><cites>FETCH-LOGICAL-c4198-8cb74c6682b370e8a6aa5ba4931c0215c96002f47e9cba118456f95a607ed9cb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1592%2Fphco.23.4.443.32119$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1592%2Fphco.23.4.443.32119$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14771798$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12680474$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Crompton, Jason A.</creatorcontrib><creatorcontrib>Somerville, Troy</creatorcontrib><creatorcontrib>Smith, Lonnie</creatorcontrib><creatorcontrib>Corbett, Jacke</creatorcontrib><creatorcontrib>Nelson, Edward</creatorcontrib><creatorcontrib>Holman, John</creatorcontrib><creatorcontrib>Shihab, Fuad S.</creatorcontrib><title>Lack of Economic Benefit with Basiliximab Induction in Living Related Donor Adult Renal Transplant Recipients</title><title>Pharmacotherapy</title><addtitle>Pharmacotherapy</addtitle><description>Study Objective. To assess the effect of basiliximab (BAS) induction therapy on acute rejection rates and overall costs in adult living related donor (LRD) renal transplant recipients.
Design. Retrospective chart review and cost‐effectiveness analysis of the first 12 months after transplantation.
Setting. University hospital and outpatient renal transplant clinic.
Patients. Sixty consecutive adult LRD renal transplant recipients.
Intervention. The treatment group received BAS 20 mg intravenously on postoperative days 0 and 4. The control group received no induction agents. Both groups received cyclosporine microemulsion, azathioprine, and corticosteroids for maintenance immunosuppression.
Measurements and Main Results. Six patients (three in each group) were excluded; three had received muromonab‐CD3 as an induction agent and three were lost to follow‐up. At 12‐months, the frequency of acute rejection episodes was 15% (4/27) in the control group and 22% (6/27) in the BAS group (NS). Renal function, as measured by average serum creatinine level, was similar at months 1, 2, 3, 6, and 12 for both groups. The frequency of infectious complications was similar in both groups. No adverse effects were associated with BAS. Mean initial hospitalization charges were $51,970.01 and $68,093.90 in the control and BAS groups, respectively (p<0.05). The control group had more readmissions (18 vs 14 in the BAS group), but the average charge/readmission was lower ($10,148.50 vs $21,952.58 in the BAS group; NS). All costs were adjusted to 2000 dollars (US).
Conclusion. Basiliximab induction therapy did not provide clear clinical efficacy benefit or prove to be cost‐effective compared with no induction in LRD recipients.</description><subject>Adult</subject><subject>Antibodies, Monoclonal - economics</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Chi-Square Distribution</subject><subject>Confidence Intervals</subject><subject>Cost-Benefit Analysis - methods</subject><subject>Cost-Benefit Analysis - statistics & numerical data</subject><subject>Female</subject><subject>Graft Rejection - drug therapy</subject><subject>Graft Rejection - economics</subject><subject>Humans</subject><subject>Kidney Transplantation - economics</subject><subject>Kidney Transplantation - statistics & numerical data</subject><subject>Living Donors - statistics & numerical data</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Recombinant Fusion Proteins</subject><subject>Retrospective Studies</subject><subject>Statistics, Nonparametric</subject><issn>0277-0008</issn><issn>1875-9114</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkEtv1DAURi0EotPCL0BC3sAuwa_4sZwppVNpCnRUYGk5jkNNHSfESR__Hg8zoltWlq7OudffB8AbjEpcKfJhuLF9SWjJSsZoSQnG6hlYYCmqQmHMnoMFIkIUCCF5BI5T-oUQwZyRl-AIEy4RE2wBuo2xt7Bv4ZntY995C1cuutZP8N5PN3Blkg_-wXemhhexme3k-wh9hBt_5-NPuHXBTK6BH7M8wmUzhynPognwejQxDcHE3cD6wbs4pVfgRWtCcq8P7wn49uns-nRdbL6cX5wuN4VlWMlC2lowy7kkNRXIScONqWrDFMU2Z6is4jlLy4RTtjYYS1bxVlWGI-GaPKIn4P1-7zD2v2eXJt35ZF3I33H9nLSgWFFWkQzSPWjHPqXRtXoYc9jxUWOkdy3rXcuaUM10bln_bTlbbw_r57pzzZNzqDUD7w6ASdaENndhfXrimBBYKJk5tefufXCP_3Nbf10vt1iSnVvsXZ8m9_DPNeOt5oKKSv_4fK75ant1-f3ySq_pH99wp1U</recordid><startdate>200304</startdate><enddate>200304</enddate><creator>Crompton, Jason A.</creator><creator>Somerville, Troy</creator><creator>Smith, Lonnie</creator><creator>Corbett, Jacke</creator><creator>Nelson, Edward</creator><creator>Holman, John</creator><creator>Shihab, Fuad S.</creator><general>Blackwell Publishing Ltd</general><general>Pharmacotherapy</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200304</creationdate><title>Lack of Economic Benefit with Basiliximab Induction in Living Related Donor Adult Renal Transplant Recipients</title><author>Crompton, Jason A. ; Somerville, Troy ; Smith, Lonnie ; Corbett, Jacke ; Nelson, Edward ; Holman, John ; Shihab, Fuad S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4198-8cb74c6682b370e8a6aa5ba4931c0215c96002f47e9cba118456f95a607ed9cb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Antibodies, Monoclonal - economics</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Chi-Square Distribution</topic><topic>Confidence Intervals</topic><topic>Cost-Benefit Analysis - methods</topic><topic>Cost-Benefit Analysis - statistics & numerical data</topic><topic>Female</topic><topic>Graft Rejection - drug therapy</topic><topic>Graft Rejection - economics</topic><topic>Humans</topic><topic>Kidney Transplantation - economics</topic><topic>Kidney Transplantation - statistics & numerical data</topic><topic>Living Donors - statistics & numerical data</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Recombinant Fusion Proteins</topic><topic>Retrospective Studies</topic><topic>Statistics, Nonparametric</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Crompton, Jason A.</creatorcontrib><creatorcontrib>Somerville, Troy</creatorcontrib><creatorcontrib>Smith, Lonnie</creatorcontrib><creatorcontrib>Corbett, Jacke</creatorcontrib><creatorcontrib>Nelson, Edward</creatorcontrib><creatorcontrib>Holman, John</creatorcontrib><creatorcontrib>Shihab, Fuad S.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Crompton, Jason A.</au><au>Somerville, Troy</au><au>Smith, Lonnie</au><au>Corbett, Jacke</au><au>Nelson, Edward</au><au>Holman, John</au><au>Shihab, Fuad S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lack of Economic Benefit with Basiliximab Induction in Living Related Donor Adult Renal Transplant Recipients</atitle><jtitle>Pharmacotherapy</jtitle><addtitle>Pharmacotherapy</addtitle><date>2003-04</date><risdate>2003</risdate><volume>23</volume><issue>4</issue><spage>443</spage><epage>450</epage><pages>443-450</pages><issn>0277-0008</issn><eissn>1875-9114</eissn><coden>PHPYDQ</coden><abstract>Study Objective. To assess the effect of basiliximab (BAS) induction therapy on acute rejection rates and overall costs in adult living related donor (LRD) renal transplant recipients.
Design. Retrospective chart review and cost‐effectiveness analysis of the first 12 months after transplantation.
Setting. University hospital and outpatient renal transplant clinic.
Patients. Sixty consecutive adult LRD renal transplant recipients.
Intervention. The treatment group received BAS 20 mg intravenously on postoperative days 0 and 4. The control group received no induction agents. Both groups received cyclosporine microemulsion, azathioprine, and corticosteroids for maintenance immunosuppression.
Measurements and Main Results. Six patients (three in each group) were excluded; three had received muromonab‐CD3 as an induction agent and three were lost to follow‐up. At 12‐months, the frequency of acute rejection episodes was 15% (4/27) in the control group and 22% (6/27) in the BAS group (NS). Renal function, as measured by average serum creatinine level, was similar at months 1, 2, 3, 6, and 12 for both groups. The frequency of infectious complications was similar in both groups. No adverse effects were associated with BAS. Mean initial hospitalization charges were $51,970.01 and $68,093.90 in the control and BAS groups, respectively (p<0.05). The control group had more readmissions (18 vs 14 in the BAS group), but the average charge/readmission was lower ($10,148.50 vs $21,952.58 in the BAS group; NS). All costs were adjusted to 2000 dollars (US).
Conclusion. Basiliximab induction therapy did not provide clear clinical efficacy benefit or prove to be cost‐effective compared with no induction in LRD recipients.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>12680474</pmid><doi>10.1592/phco.23.4.443.32119</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0277-0008 |
| ispartof | Pharmacotherapy, 2003-04, Vol.23 (4), p.443-450 |
| issn | 0277-0008 1875-9114 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73193452 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Adult Antibodies, Monoclonal - economics Antibodies, Monoclonal - therapeutic use Biological and medical sciences Chi-Square Distribution Confidence Intervals Cost-Benefit Analysis - methods Cost-Benefit Analysis - statistics & numerical data Female Graft Rejection - drug therapy Graft Rejection - economics Humans Kidney Transplantation - economics Kidney Transplantation - statistics & numerical data Living Donors - statistics & numerical data Male Medical sciences Middle Aged Recombinant Fusion Proteins Retrospective Studies Statistics, Nonparametric |
| title | Lack of Economic Benefit with Basiliximab Induction in Living Related Donor Adult Renal Transplant Recipients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T14%3A17%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lack%20of%20Economic%20Benefit%20with%20Basiliximab%20Induction%20in%20Living%20Related%20Donor%20Adult%20Renal%20Transplant%20Recipients&rft.jtitle=Pharmacotherapy&rft.au=Crompton,%20Jason%20A.&rft.date=2003-04&rft.volume=23&rft.issue=4&rft.spage=443&rft.epage=450&rft.pages=443-450&rft.issn=0277-0008&rft.eissn=1875-9114&rft.coden=PHPYDQ&rft_id=info:doi/10.1592/phco.23.4.443.32119&rft_dat=%3Cproquest_cross%3E73193452%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73193452&rft_id=info:pmid/12680474&rfr_iscdi=true |